Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Gains from Sales and Divestitures (2019 - 2025)

Opus Genetics has reported Gains from Sales and Divestitures over the past 5 years, most recently at $664734.0 for Q4 2025.

  • Quarterly Gains from Sales and Divestitures rose 111.59% to $664734.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $664734.0 through Dec 2025, up 111.59% year-over-year, with the annual reading at $664734.0 for FY2025, 111.59% up from the prior year.
  • Gains from Sales and Divestitures was $664734.0 for Q4 2025 at Opus Genetics, up from $278858.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $664734.0 in Q4 2025 and troughed at $33614.0 in Q2 2023.
  • The 4-year median for Gains from Sales and Divestitures is $40000.0 (2021), against an average of $144306.3.
  • Year-over-year, Gains from Sales and Divestitures surged 834.62% in 2024 and then skyrocketed 111.59% in 2025.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $40000.0 in 2021, then dropped by 15.96% to $33614.0 in 2023, then surged by 834.62% to $314162.0 in 2024, then surged by 111.59% to $664734.0 in 2025.
  • Per Business Quant, the three most recent readings for IRD's Gains from Sales and Divestitures are $664734.0 (Q4 2025), $278858.0 (Q2 2025), and $102676.0 (Q1 2025).